The 13D proxy action is to benefit new large investors who will buy shares in a secondary and will be allowed to short sell CYDY with a prior agreement to be allocated shares in the secondary offering possibly with warrants at a below market price. It happens very frequently in pre-revenue biotech and is legal to do. Easy pickings from retail, they will without a doubt legally rob current retail investors in this manner. Your bear thesis opinions are water under the bridge at this point. The 13 D group poses a clear danger of current shareholders being legally robbed in a dilutive secondary stock offering.
I'm not saying that it is the intention of the 13D group, but a reverse split might be 5 for 1 or 10 for 1 or 20 for one, but I doubt that it would be 100 for 1. 620,866,391 shares outstanding is a lot of shares for a company with failed clinical trials.
News 
Market Data 
Discover 
